行情

CTXR

CTXR

CITIUS PHARMACEU
NASDAQ

实时行情|Nasdaq Last Sale

1.130
-0.120
-9.60%
盘后: 1.120 -0.01 -0.89% 17:30 01/27 EST
开盘
1.220
昨收
1.250
最高
1.250
最低
1.130
成交量
67.02万
成交额
--
52周最高
1.590
52周最低
0.4000
市值
3,269.15万
市盈率(TTM)
-1.4528
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CTXR 新闻

  • 瑞士国家旅游局:愿与中国旅游业者共克时艰
  • 中国新闻网.13分钟前
  • 日本政府提名支持宽松的经济学家安达诚司为央行执委
  • 新浪财经.19分钟前
  • 苹果上半年拟生产8000万部iPhone 全年增产10%
  • IT之家.21分钟前
  • 巴西反垄断监管机构批准波音与巴航工业合作计划
  • 新华网.42分钟前

更多

所属板块

制药
-0.42%
制药与医学研究
-0.51%

热门股票

名称
价格
涨跌幅

CTXR 简况

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
展开

Webull提供Citius Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。